PLoS One 10 (4), e0123454
By BPC 157 therapy, the principle of upgrading minor vessels by prompt activation of the vascular collaterals (i.e., azygos vein direct blood flow delivery) is commonly operative to counteract the occlusion/occlusion-like syndrome, major vascular and multiorgan failure peripherally and centrally induced in rats [26,27]
BPC-157 only emerged as a new pharmaceutical a few years back but has already gained much attention from the scientific community and the fitness industry
They also found that the cells released this substance into the liquid they were growing in
GHK-Cu does not inhibit ghrelin, does not stimulate GLP-1 receptors, and does not meaningfully alter insulin sensitivity
If you see GHK-Cu before-and-after photos showing dramatic results in days or a week, those are almost certainly from injectable protocols, not from a cream